位置:首页 > 产品库 > Taurochenodeoxycholic acid sodium
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Taurochenodeoxycholic acid sodium
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Taurochenodeoxycholic acid sodium图片
CAS NO:6009-98-9
包装与价格:
包装价格(元)
20 mg询价
1 mL*10 mM(in DMSO)询价

Sodium taurochenodeoxycholate
牛磺鹅去氧胆酸钠盐
牛磺鹅去氧胆酸钠
TaurocheNODeoxycholic acid sodium 是动物胆汁酸的主要生物活性物质之一。它可诱导细胞凋亡,具有抗炎和免疫调节作用。

产品描述

Sodium taurochenodeoxycholate is one of the main bioactive substances of animals' bile acid. Sodium taurochenodeoxycholate induces apoptosis and shows obvious anti-inflammatory and immune regulation properties. It can increase glucose-induced insulin secretion and stimulate the electrical activity of α2-cells and enhance cytosolic Ca(2+) concentration ([Ca(2+)](c)).

体外活性

Experiments were performed with islets from wild-type, farnesoid X receptor (FXR) knockout (KO), and β-cell ATP-dependent K(+) (K(ATP)) channel gene SUR1 (ABCC8) KO mice, respectively. Sodium taurochenodeoxycholate (TCDC) increased glucose-induced insulin secretion. This effect was mimicked by the FXR agonist GW4064 and suppressed by the FXR antagonist guggulsterone. TCDC and GW4064 stimulated the electrical activity of β-cells and enhanced cytosolic Ca(2+) concentration ([Ca(2+)](c)). These effects were blunted by guggulsterone. Sodium ursodeoxycholate, which has a much lower affinity to FXR than TCDC, had no effect on [Ca(2+)](c) and insulin secretion. FXR activation by TCDC is suggested to inhibit K(ATP) current. The decline in K(ATP) channel activity by TCDC was only observed in β-cells with intact metabolism and was reversed by guggulsterone. TCDC did not alter insulin secretion in islets of SUR1-KO or FXR-KO mice. TCDC did not change islet cell apoptosis.

Cas No.

6009-98-9

分子式

C26H45NNaO6S

分子量

522.69

别名

Sodium taurochenodeoxycholate;牛磺鹅去氧胆酸钠盐;牛磺鹅去氧胆酸钠

储存和溶解度

DMSO:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024